2. Academic Validation
  3. Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo

  • Drug Des Devel Ther. 2020 Aug 24;14:3435-3447. doi: 10.2147/DDDT.S256867.
Jiaxuan Peng  # 1,  Kangxian Zhao  # 2,  Jiling Zhu  # 3,  Yanben Wang 4 5,  Peng Sun 2,  Qichang Yang 2,  Tan Zhang 4,  Weiqi Han 4,  Wenjun Hu 4,  Wanlei Yang 4,  Jianwei Ruan 6,  Yu Qian 1 2 4
Affiliations

Affiliations

  • 1 Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Guangxi 530021, People's Republic of China.
  • 2 The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, People's Republic of China.
  • 3 Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang 312000, People's Republic of China.
  • 4 Department of Orthopaedics, Shaoxing People's Hospital, Zhejiang University School of Medicine, Shaoxing 312000, Zhejiang, People's Republic of China.
  • 5 Department of Orthopaedics, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
  • 6 Department of Orthopaedics, Taizhou Municipal Hospital, Taizhou 318000, Zhejiang, Republic of China.
  • # Contributed equally.
PMID: 32943842 DOI: 10.2147/DDDT.S256867
Abstract

Introduction: Osteoclasts are giant polynuclear cells; their main function is bone resorption. An increased number of osteoclasts and enhanced bone resorption exert significant effects on osteoclast-related bone-lytic diseases, including osteoporosis. Given the limitations of current therapies for osteolytic diseases, it is urgently required to develop safer and more effective alternatives. Sarsasapogenin, a major sapogenin from Anemarrhena asphodeloides Bunge, possesses potent antitumor effects and inhibits NF-κB and MAPK signaling. However, the manner in which it affects osteoclasts is unclear.

Methods: We investigated the effects of anti-osteoclastogenic and anti-resorptive of sarsasapogenin on bone marrow-derived osteoclasts.

Results: Sarsasapogenin inhibited multiple RANKL-induced signaling cascades, thereby inhibiting the induction of key osteoclast transcription factor NFATc1. The in vivo and in vitro results were consistent: sarsasapogenin treatment protected against bone loss in a mouse osteolysis model induced by lipopolysaccharide.

Conclusion: Our research confirms that sarsasapogenin can be used as a new treatment for osteoclast-related osteolytic diseases.

Keywords

MAPK; NF-κB; NFATc1; osteoclast; osteoclastogenesis; sarsasapogenin; therapeutics.

Figures
Products